Company intelligence / Profile preview

TeneoFour

Newark, California, United Statesamgen.com ↗

Ownership: Private
Development stage: Phase 1

Overview

TeneoFour's lead candidate TNB-738 is a CD38 inhibitor that has shown promise in rejuvenating energy metabolism in aged mice. The drug works by blocking the enzyme functions of CD38, potentially driving higher NAD levels, improving mitochondrial health, reducing hyperinflammation, and reversing fibrosis. As of May 2025, TNB-738 is in Phase 1 clinical trials.

Therapeutic areas: ImmunologyMetabolic Disorders
Modalities: Monoclonal antibodiesBispecific antibodiesHuman Heavy-Chain Antibodies
Industry: Biotech

Drug pipeline

1 asset

TNB-738

Phase 1

Indications: Inflammatory disorders, Metabolic disorders

Beyond the preview

Go deeper on TeneoFour.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TeneoFour.

Explore the full profile